ArticleAdvances in radiation oncology2026
Evaluation of Hemorrhage Risk and Predictors Following Stereotactic Radiosurgery for Cerebral Arteriovenous Malformations: A Retrospective Single-center Study.
Article in Advances in radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Radiation therapy is a well-established treatment method for cerebral arteriovenous malformations (AVMs) used in combination with other treatment modalities or alone. This study evaluated the postintervention bleeding risk of cerebral AVMs treated with stereotactic radiosurgery (SRS) using a linear accelerator (LINAC) and identified predictors of posttherapeutic hemorrhage. Methods and Materials: A retrospective analysis was conducted on 134 consecutive patients with AVMs treated with LINAC-based SRS between 1983 and 2022 at the department for Radiotherapy and Radiation Oncology at the Marburg University Hospital. Patients were followed for a median of 49 months. Statistical analysis was performed to assess the influence of variables such as AVM grade, prior treatment, SRS dose, and other clinical factors on post-SRS bleeding risk. Results: Nine post-SRS hemorrhages occurred for a total of 816.6 patient-years, resulting in an overall bleeding rate of 6.7% and an annual rate of 1.1%. No bleeding-related fatalities were recorded. Higher Spetzler-Martin AVM grade ( Conclusion: LINAC-based SRS for AVMs is associated with with a relatively low risk of posttreatment hemorrhage, with an annual bleeding rate lower than that of untreated AVMs and comparable with the risk found in previous studies. Higher AVM grades and prior treatments are key predictors of post-SRS hemorrhage. Given the possibility of hemorrhage even after angiographic obliteration, close long-term follow-up is recommended. Modern imaging techniques may enhance postobliteration monitoring in high-risk cases.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.